Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (24...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-07-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Online Access: | https://www.dovepress.com/corrigendumlong-term-safety-profile-of-tolvaptan-in-autosomal-dominant-peer-reviewed-article-DHPS |